Laboratory methods for the diagnosis of invasive mycoses

Invasive mycoses are serious complications in oncohaematologic and surgical patients. Most of them are caused by Candida but other emergent fungi are changing the disease spectrum. Absence of specific symptoms complicates diagnosis. Recovery of fungi from blood and deep specimens remains an insensitive diagnosis, leading to delayed treatment and high mortality. Management of invasive mycoses presents a therapeutic and diagnostic challenge because prompt initiation of targeted antifungal treatment is lifesaving.

An ideal test for diagnosing an invasive fungal infection should have good performance characteristics, give a high level of certainty with respect to the presence or absence of disease, and should become positive at an early stage of infection. However, culture lacks sensitivity, histology requires invasive procedures, imaging lacks specificity, and fungal biomarkers detection requires higher standardization.

There is not available a single test with all these features, and combining information from different laboratory tests and clinical procedures is required. Biomarkers, such as 1,3-β-D-glucan (BG), galactomannan (GM), glucuronoxylomannan (GXM) and mannan, anti-Candida antibodies, or fungal DNA can be useful diagnostic tools.

BG is a panfungal marker that can be present early in the blood and other biological fluids from patients suffering from invasive fungal infections. GM may be detected in the course of invasive aspergillosis and be positive prior to the clinical and radiological suspicions for infection. GXM is essential in the diagnosis of cryptococcal meningitis. Mannan and anti-Candida antibody detections are helpful for the diagnosis of invasive candidiasis. DNA detection by PCR is a promising diagnostic tool under validation before recommendation for clinical use.

Non-culture methods based in biomarkers detection, allow rapid and more-sensitive diagnosis, compared with traditional microbiological diagnosis. Their usefulness increases when samples from patients are tested regularly. BG and GM detection are useful tests for the diagnosis of invasive aspergillosis in high-risk patients with haematological malignancies. In addition, combination of GM and PCR-based testing could also help identify cases of invasive aspergillosis with poor prognosis. One possible diagnostic approach would be to screen high-risk patients for the presence of biomarkers during the periods of highest risk. This selection is very important, because the incidence of invasive mycoses, especially when it is very low, greatly influences the positive predictive and negative predictive values of diagnostic methods. For instance, when the incidence of invasive aspergillosis is 0.5%, as in kidney transplant recipients, only one out of 10 patients with a positive GM and one out of 70 with a positive PCR will actually suffer for invasive aspergillosis.

Although some questions need to be solved, such as kinetics and release of biomarkers, assay performances in different groups of patients, or the effects of antifungal treatment, the broader use of these assays could help to understand better the pathogenesis of invasive mycoses and improve their diagnosis, treatment and prognosis. Moreover, currently most tests lack standardization, and a future consensus will be necessary for facilitating large, prospective, clinical trials focused on the integration of these techniques into clinical decision-making.

In conclusion, the implementation of non-culture based methods, alone or in combination with other microbiological tests, into the clinical setting could improve therapeutic approaches and outcome, by treatment monitoring, and personalizing the therapy.

Additional information available at Enfermedades Infecciosas y Microbiología Clínica

Epidemiology of candidaemia and invasive candidiasis

Invasive candidiasisis a leading cause of mortality. Candidaemia is the most common clinical presentation of invasive candidiasis but more that 30% of these infections do not yield positive blood cultures. Candida albicans remains the predominant aetiology, accounting for 50% of all cases. However, there has been an epidemiological shift in the last decades. Some species of Candida different to C. albicans have emerged as an important cause of severe candidaemia as they can exhibit resistance to fluconazole and other antifungal agents. Moreover, there is a different distribution of non C. albicans Candida species in relationship to patients’ and hospital characteristics. Thus, Candida parapsilosis has been associated to candidaemia in neonates and young adults. This species usually has an exogenously origin and contaminates medical devices, causing central venous catheter-associated candidaemias.Candida glabrataCandida tropicalis and Candida krusei are isolated in blood cultures from older patients (>65 years) with important risk factors, such as major abdominal surgery, solid tumours and haematologic malignancies, transplants, and/or prolonged treatment with corticoids. Moreover, important geographical differences in the distribution of the Candida species different to C. albicans causing invasive candidiasis have been reported: C. parapsilosis predominates in Australia, Latin America and Mediterranean countries of Africa, Asia and Europe. In contrast, C. glabrata has an important aetiological role in USA and Central and Northern Europe. Finally, an important and worrying issue is that mortality due to invasive candidiasis remains unacceptably high.

Full text available at Revista Iberoamericana de Micología


¡Feliz año nuevo 2014! Urte Berri On! Happy New Year 2014! Feliç any 2014! Heureux 2014! Счастливый 2014! Frohes neues Jahr 2014!

Feliz 2014 2Feliz 2014 1Realizado por Tania Quindós González